Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. Issue 4 (22nd December 2022)

• Record Type: Journal Article
• Authors: Jackson, Lindsey M; Moldovan, George-Lucian
• Is Part Of: NAR cancer. Volumer 4:Issue 4(2022)
• Publication Date: 2022-12-22
• Subjects: Cancer -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 616.994
• DOI: 10.1093/narcan/zcac042
• Languages: English
• ISSNs: 2632-8674

Abstract

Abstract: The discovery of synthetic lethality as a result of the combined loss of PARP1 and BRCA has revolutionized the treatment of DNA repair-deficient cancers. With the development of PARP inhibitors, patients displaying germline or somatic mutations in BRCA1 or BRCA2 were presented with a novel therapeutic strategy. However, a large subset of patients do not respond to PARP inhibitors. Furthermore, many of those who do respond eventually acquire resistance. As such, combating de novo and acquired resistance to PARP inhibitors remains an obstacle in achieving durable responses in patients. In this review, we touch on some of the key mechanisms of PARP inhibitor resistance, including restoration of homologous recombination, replication fork stabilization and suppression of single-stranded DNA gap accumulation, as well as address novel approaches for overcoming PARP inhibitor resistance. Graphical Abstract: